The US Food and Drug Administration has reported that it is to issue a letter by the end of this month on cardiovascular events associated with clozapine in bioequivalence trials with healthy volunteers. The drafting of the letter follows submissions by Sandoz and Zenith Labs reporting these side effects.
Zenith suspended trials of its generic formulation of clozapine after four patients suffered "serious adverse events." Zenith added that it is unlikely that other firms will accept Sandoz' claim that cardiac arrest is possible in normal patients. Clozapine, which is marketed by Sandoz under the tradename Clozaril, came off-patent in September. Bioequivalence testing in schizophrenics is likely to be more expensive than using healthy volunteers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze